Modelus, a Johns Hopkins Carey‑linked venture, rolled out an AI analytics platform that standardizes organoid experiments to accelerate drug discovery and reduce lab costs. The company reported pilot results that cut organoid timelines and saved research dollars, positioning the platform as a reproducibility and regulatory compliance layer for translational biology labs. INSEAD‑backed Gadi.ai introduced a rooftop solar AI agent that automates post‑installation service and performance forecasting for installers. Early commercial pilots connected more than 1,000 systems and showed payback potential in service retention and upgrade conversion. University tech‑transfer offices cited both examples as evidence that lab‑derived software can generate recurring revenue and reduce dependency on one‑time licensing by offering SaaS models that lock in long‑term practitioner customers.